Inclusion Criteria:

- histologically confirmed HCC or diagnosis of HCC according to AASLD-guidelines

- macroscopic tumor

- liver-confined disease without extrahepatic disease as diagnosed by CT, MRT,
ultrasound and bone scan

- minimal distance of tumor edge to the intestines of 1cm

- age ≥ 18 years of age

- Karnofsky Performance Score ³60

- For women with childbearing potential, (and men) adequate contraception.

- Ability of subject to understand character and individual consequences of the
clinical trial

- Written informed consent (must be available before enrolment in the trial)

Exclusion Criteria:

- refusal of the patients to take part in the study

- previous radiotherapy of the hepatobiliary system

- margin of < 1cm between tumor edge and intestines

- Patients who have not yet recovered from acute toxicities of prior therapies

- Known carcinoma < 2 years ago (excluding Carcinoma in situ of the cervix, basal cell
carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment
interfering with study therapy

- Pregnant or lactating women

- Participation in another clinical study or observation period of competing trials,
respectively